A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
    • 03 Oct 2011 Actual initiation date changed from Nov 2008 to Feb 2009 as reported by ClinicalTrials.gov.
    • 18 Jul 2011 Actual end date 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top